Want to see ITRMF full AI Analyst Report?
Iterum Therapeutics (ITRMF) AI Stock Analysis
Iterum Therapeutics
(Other OTC:ITRMF)
The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.
Iterum Therapeutics (ITRMF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.66M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 2.60
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Iterum Therapeutics Business Overview & Revenue Model
Company Description
Iterum Therapeutics plc, an Irish pharmaceutical company founded in Dublin in 2015, is dedicated to the development and commercialization of treatments for bacterial infections that are resistant to existing drugs. Operating in Ireland, Bermuda, and...
How the Company Makes Money
null
Iterum Therapeutics Earnings Call Summary
The earnings call highlighted the successful early stages of Orlynda's launch and positive market feedback, indicating potential for growth. However, financial challenges remain due to limited initial revenue, increased expenses, and the need for additional capital.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
In the third quarter of 2025, Iterum Therapeutics reported net product sales of $400,000 with the launch of Orlynda in the U.S. in August 2025. The company successfully generated over 280 prescriptions through more than 100 unique prescribers, indicating growing physician and patient engagement. Approximately 40% of prescriptions have been filled through payer approval processes, aligning with expectations despite awaiting broader payer coverage. Iterum anticipates 2026 net product revenue to range between $5 million and $15 million, supported by expanding insurance coverage, particularly with a recent signed rebate agreement with a top Medicare Part D pharmacy benefit manager. Operating expenses for 2026 are projected between $25 million and $30 million, with current cash reserves expected to fund operations into 2026. The company aims to raise additional capital to sustain commercialization efforts, targeting high-value territories and potentially expanding further.
Iterum Therapeutics Financial Statement Overview
Summary
Very limited TTM revenue ($0.39M) with continued large losses (net loss ~$27.0M) and ongoing cash burn (operating/free cash flow about -$19.9M TTM). While losses, cash burn, and debt have improved versus prior years, negative shareholders’ equity (about -$7.4M TTM) and debt exceeding assets keep financial risk high.
Income Statement
12Very NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 390.00K | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -668.00K | -254.00K | -1.75M | -1.80M | -2.10M | -161.00K |
| EBITDA | -23.07M | -21.73M | -34.58M | -39.97M | -83.20M | -36.01M |
| Net Income | -26.96M | -24.77M | -38.37M | -44.43M | -91.56M | -52.01M |
Balance Sheet | ||||||
| Total Assets | 32.50M | 44.59M | 26.26M | 66.83M | 91.51M | 32.79M |
| Cash, Cash Equivalents and Short-Term Investments | 11.00M | 24.13M | 23.93M | 60.80M | 81.34M | 14.57M |
| Total Debt | 33.73M | 45.53M | 18.96M | 30.10M | 30.43M | 48.08M |
| Total Liabilities | 39.88M | 48.68M | 32.66M | 38.83M | 41.27M | 83.35M |
| Stockholders Equity | -7.38M | -4.08M | -6.40M | 28.00M | 50.23M | -50.56M |
Cash Flow | ||||||
| Free Cash Flow | -19.93M | -26.77M | -39.34M | -18.54M | -15.90M | -54.54M |
| Operating Cash Flow | -19.91M | -26.77M | -39.33M | -18.47M | -15.84M | -54.53M |
| Investing Cash Flow | 1.09M | 18.21M | 23.34M | 13.96M | -54.59M | -11.00K |
| Financing Cash Flow | 16.27M | 26.69M | 1.03M | -1.82M | 83.13M | 64.47M |
Iterum Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITRMF, the sentiment is Neutral. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 44.35 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ITRMF.
Iterum Therapeutics Risk Analysis
Iterum Therapeutics disclosed 88 risk factors in its most recent earnings report. Iterum Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksIterum Therapeutics Peers Comparison
Overall Rating
EVAX61Neutral- ITRMF43Neutral
ACXP41Neutral
GOVX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| EVAX | 61Neutral | $24.77M | -0.45 | -61.39% | ― | 134.15% | 82.33% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ITRMF | 43Neutral | $53 | -0.14 | 274.90% | ― | ― | ― |
| ACXP | 41Neutral | $5.73M | -0.27 | -124.74% | ― | ― | 71.66% |
| GOVX | 40Underperform | $1.70M | -0.01 | -743.66% | ― | -100.00% | 77.63% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ITRMF | Iterum Therapeutics | 0.03 | -0.57 | -94.83% | |
| GOVX | Geovax Labs, Inc. | 0.16 | -12.68 | -98.77% | |
| OGEN | Oragenics Inc | 0.35 | -0.77 | -68.76% | |
| EVAX | Evaxion Biotech A/S Adr | 2.76 | -3.62 | -56.74% | |
| ACXP | Acurx Pharmaceuticals Llc | 0.94 | -3.79 | -80.02% | |
| VRAX | Virax Biolabs Group Ltd. Class A | 1.18 | -10.85 | -90.19% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 30, 2025